Protocol Ledger

NCT06841055 · Phase II · RECRUITING

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

Interventional Phase II clinical trial protocol NCT06841055 sponsored by BioNTech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-03 Enrollment: 60 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06841055
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)60 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06841055
Protocol FieldVerified Registry Value
NCT IdentifierNCT06841055
Consolidated Lead SponsorBioNTech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment60 participants (ESTIMATED)
Registered Start Date2025-03-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06841055
Hospital Research SiteLocationSite Profile
Moffitt Cancer CenterTampa, FLOpen Hospital Dossier ->
NYU Langone Health and Perlmutter Cancer CenterNew York, NYOpen Hospital Dossier ->
Chungbuk National University HospitalCheongju-si, South KoreaOpen Hospital Dossier ->
Gachon University Gil Medical CenterIncheon, South KoreaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI